{"id":"W3093975417","doi":"10.1182/bloodadvances.2020002119","title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Genentech; National Institutes of Health; Astellas Pharma; MacroGenics; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Memorial Sloan-Kettering Cancer Center; Gilead Sciences; Cardinal Health; Amgen; Pfizer; PTC Therapeutics; Celgene; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Ruxolitinib; Decitabine; Medicine; Myeloproliferative neoplasm; Internal medicine; Phases of clinical research; Confidence interval; Population; Clinical endpoint; Oncology; Gastroenterology; Clinical trial; Myelofibrosis; Surgery; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001666234,0.001032949,0.001469435,0.0003717678,0.0002830032,0.000657222,0.0005581444,0.0008954846,0.002844688],"category_scores_gemma":[0.0009671877,0.0004546671,0.0007383997,0.0002778306,0.000502494,0.0007212173,0.0003390085,0.002120407,0.0005486722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006057434,"about_ca_system_score_gemma":0.00103975,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005169915,"about_ca_topic_score_gemma":0.001389434,"domain_scores_codex":[0.9995176,0.0002871261,0.00001975543,0.00006487147,0.00003699798,0.0000735724],"domain_scores_gemma":[0.9995661,0.00007904398,0.00008077642,0.00003382718,0.0000277192,0.00021246],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7284992,0.09756401,0.008935804,0.0005557814,0.001141185,0.0004974109,0.0003054083,0.002779431,0.03308484,0.0005900941,0.004127112,0.1219197],"study_design_scores_gemma":[0.6445585,0.339823,0.008318701,0.00002600454,0.0002172522,0.0003389302,0.00004157099,0.001611863,0.002155058,0.0002105533,0.002679484,0.00001895217],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991591,0.00146875,0.0005619951,0.0004571491,0.00009010559,0.003330013,0.0006797886,0.00005636213,0.001764773],"genre_scores_gemma":[0.9878297,0.001007897,0.002250104,0.0007167677,0.0001463045,0.003685045,0.001899222,0.00001858003,0.002446451],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002844688,"threshold_uncertainty_score":0.009516418,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01948406931468189,"score_gpt":0.3019457263841157,"score_spread":0.2824616570694338,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}